---
id: ash-vte-cancer-update-2024
title: "ASH 2024 Guidelines Update for Management of VTE in Cancer"
short_title: "VTE in Cancer - Update"
organization: American Society of Hematology
country: United States
url: https://ashpublications.org/bloodadvances/article/8/16/4133/516258
specialty: hematology
guideline_type: clinical-practice
evidence_system: grade
conditions:
  - Cancer-Associated VTE
  - Deep Vein Thrombosis
  - Pulmonary Embolism
tags:
  - VTE
  - cancer
  - anticoagulation
  - DOAC
publication_date: 2024-08-15
previous_version_date: 2021-01-01
status: current
supersedes: ash-cancer-vte-2021
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline update provides recommendations for prevention and treatment of venous thromboembolism in patients with cancer.

## Key Recommendations

### Primary Prophylaxis - Ambulatory
- Not routinely recommended for all ambulatory patients
- Consider for high-risk outpatients starting chemotherapy (Khorana score ≥2)
- Apixaban or rivaroxaban options if prophylaxis given

### Primary Prophylaxis - Hospitalized
- Pharmacologic prophylaxis for hospitalized medical/surgical cancer patients
- LMWH, UFH, or fondaparinux
- Extended prophylaxis post-abdominal/pelvic cancer surgery (4 weeks)

### Treatment - Acute VTE
**DOACs Preferred:**
- Apixaban, edoxaban, rivaroxaban
- Preferred over LMWH for most patients

**LMWH Preferred:**
- GI or GU malignancy with high mucosal bleeding risk
- Drug interactions with systemic cancer therapy
- Extremes of body weight
- Severe renal impairment

### Duration of Anticoagulation
- Minimum 3-6 months
- Continue while cancer is active or on treatment
- Reassess periodically for ongoing indication

### Catheter-Associated Thrombosis
- Anticoagulate without routine catheter removal (if functional)
- Duration: Minimum 3 months or while catheter in place

### Incidental VTE
- Treat similar to symptomatic VTE if segmental or more proximal

### Recurrent VTE on Anticoagulation
- Switch anticoagulant class (DOAC ↔ LMWH)
- Increase LMWH dose if already on LMWH
- Consider IVC filter only if anticoagulation absolutely contraindicated

### Special Populations
- Brain tumors: Anticoagulation generally safe; individualize
- Thrombocytopenia: Dose-adjust or hold based on platelet count
